Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.64 |
| ▸ | ACE | P12821 | 3/20 | 0.64 |
| ▸ | GRN | P28799 | 6/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 6/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.32 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.32 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655474 | 1.00 | ACE2 (0.64) | ACE2ACEGRNSORT1CYP11B1 | |
| SCHEMBL3680172 | 0.91 | ACE2 (0.52) | ACE2ACEGRNSORT1CYP11B1 | |
| SCHEMBL7531333 | 0.90 | ACE2 (0.55) | ACE2ACEGRNSORT1CYP11B1 | |
| SCHEMBL3709303 | 0.90 | ACE2 (0.52) | ACE2ACECYP11B1CYP11B2MAPK1 | |
| SCHEMBL7424864 | 0.89 | ACE2 (0.54) | ACE2ACEGRNSORT1CYP11B1 | |
| SCHEMBL7382791 | 0.88 | ACE2 (0.49) | ACE2ACEGRNSORT1CYP11B1 | |
| SCHEMBL7391523 | 0.88 | ACE2 (0.48) | ACE2ACEGRNSORT1CYP11B1 | |
| SCHEMBL7422082 | 0.88 | ACE2 (0.48) | ACE2ACEGRNSORT1CYP11B1 | |
| SCHEMBL7384416 | 0.87 | ACE2 (0.52) | ACE2ACEGRNSORT1CYP11B1 | |
| SCHEMBL7421732 | 0.87 | ACE2 (0.54) | ACE2ACEGRNSORT1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010093804-A1 | ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICALS, INC. (US) | 2010-08-19 | — | — | WO | claimed |
| WO-2021202399-A1 | METHODS OF TREATING CORONAVIRUS INFECTIONS USING ANGIOTENSIN-CONVERTING ENZYME 2 INHIBITORS | KUMUDA, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3717077-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2020-10-07 | — | — | EP | disclosed |
| WO-2010093804-A1 | ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICALS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2008031013-A1 | METHOD FOR TREATING INFLAMMATORY DISEASES OF THE DIGESTIVE TRACT | GENE LOGIC INC. (US) | 2008-03-13 | — | — | WO | disclosed |